Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Wilcoxon Rank-Sum Test01:21

Wilcoxon Rank-Sum Test

826
The Wilcoxon rank-sum test, also known as the Mann-Whitney U test, is a nonparametric test used to determine if there is a significant difference between the distributions of two independent samples. This test is designed specifically for two independent populations and has the following key requirements:
826
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K
Allergic Reactions02:06

Allergic Reactions

33.1K
Overview
33.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.6K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An update on the pharmacotherapy of ANCA-associated vasculitis.

Expert review of clinical immunology·2026
Same author

The Internet of Vehicles (IoV) and privacy-preserving systems.

Scientific reports·2026
Same author

Imbalance of type I and II interferon pathways is associated with pain perception in Sjogren's disease: a real-life study.

Frontiers in immunology·2026
Same author

Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.

Rheumatology (Oxford, England)·2026
Same author

Emerging approaches to difficult-to-manage axial spondyloarthritis.

Expert opinion on pharmacotherapy·2026
Same author

[Biological treatments for rheumatology : specific situations and risks].

Revue medicale suisse·2026

Related Experiment Videos

Dr. Wiland, et al, reply

Piotr Wiland1, Jean Dudler2, Douglas Veale3

  • 1Head of Department, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland; pwiland1@gmail.com.

The Journal of Rheumatology
|February 3, 2017
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos